Consolidated Statements of Operations - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Consolidated Statement of Operations [Abstract]
Revenue	$ 29,000	$ 106,000
Operating expenses
Research and development	1,490,000	1,980,000
General and administrative	1,898,000	2,644,000
Total operating expenses	3,388,000	4,624,000
Loss from operations	(3,359,000)	(4,518,000)
Other income (expense)
Change in fair value of derivative liabilities	114,000	1,406,000
Other expense, net	(1,000)
Total other income (expense)	113,000	1,406,000
Net (loss) income	(3,246,000)	(3,112,000)
Accretion of Series B redeemable convertible preferred stock		(1,725,000)
Net (loss) income attributable to common stockholders	$ (3,246,000)	$ (4,837,000)
Per share information:
Net loss per share of common stock - basic & diluted	$ (1.94)	$ (8.22)
Weighted average number of shares of common stock outstanding - basic & diluted (in shares)	1,677,497	588,350